SLC5A2 and chronic kidney disease: Nevertheless, based on the evidence of kidney and cardiovascular protection offered by SGLT2 inhibitors in CKD patients, our prediction model may assist physicians in decision making regarding recommending this drug for sepsis survivors who are at a high risk of ERSD.